1. Effectiveness and Safety of Direct-Acting Antivirals in the Treatment of Chronic Hepatitis C: A Real-life Study in Northeastern Brazil.
- Author
-
Hyppolito EB, Ramos AN Jr, Teixeira LP, Bezerra AM, Mendes LA, Silva TL, Lima JMC, Arruda ÉAG, Guerra EJ, Tavares MMS, Lima CEP, Esmeraldo TM, Pessoa FSRP, Pierre AMM, Pereira KB, Araújo Filho AH, Linhares LMC, Ferreira AF, and Pires Neto RDJ
- Subjects
- Humans, Male, Middle Aged, Female, Retrospective Studies, Brazil, Treatment Outcome, Aged, Drug Therapy, Combination, Adult, Hepatitis C, Chronic drug therapy, Antiviral Agents therapeutic use, Antiviral Agents adverse effects, Sustained Virologic Response
- Abstract
Background: This study aimed to evaluate the effectiveness and safety of direct-acting antivirals (DAAs) for hepatitis C treatment by measuring sustained virologic response (SVR) and serious adverse events to help design effective interventions for reducing disease prevalence., Methods: This was a retrospective, observational, real-life study of patients with chronic hepatitis C receiving DAA treatment in the state of Ceará, Brazil. Data were collected in REDCap and analyzed using R® software by the Student's t, chi-square, and Fisher's exact tests, with a significance level of 5%., Results: In this study, 1075 patients who were diagnosed with hepatitis C infection between October 2015 and October 2023 were included. The mean age of the participants was 56.6 ± 11 years and 60.2% were men. The sample included 51 HIV-infected patients (6.6%), 166 (15,4%) liver transplant recipients, 34 (3,1%) kidney transplant recipients, and 446 patients with cirrhosis (41.4%). The overall SVR rate was 96.4%. The sofosbuvir/daclatasvir/ribavirin regimen used in 354 (32.9%) patients achieved an SVR of 96%. The cure rate was 96.5%, with a lower SVR in patients with cirrhosis (93.4%) than in those with less severe fibrosis (97.9%) (p=0.0015). Serious adverse events associated with ribavirin use occurred in 3.5% of patients., Conclusions: DAA treatment for hepatitis C achieved SVR in real life in all patient profiles, including transplant recipients, HIV carriers, and patients with cirrhosis. Although these drugs are safe, a few decompensated patients with cirrhosis died during treatment.
- Published
- 2024
- Full Text
- View/download PDF